Cargando…
Barriers to overcoming immunotherapy resistance in glioblastoma
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, known for its poor prognosis and high recurrence rate. Current standard of care includes surgical resection followed by combined radiotherapy and chemotherapy. Although immunotherapies have yielded promising results in h...
Autores principales: | Gillette, Julia S., Wang, Elaina J., Dowd, Richard S., Toms, Steven A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232794/ https://www.ncbi.nlm.nih.gov/pubmed/37275361 http://dx.doi.org/10.3389/fmed.2023.1175507 |
Ejemplares similares
-
Overcoming delivery barriers in immunotherapy for glioblastoma
por: Rui, Yuan, et al.
Publicado: (2021) -
Immunotherapy Resistance in Glioblastoma
por: Wang, Elaina J., et al.
Publicado: (2021) -
Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers
por: Lechpammer, Mirna, et al.
Publicado: (2022) -
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
por: Adhikaree, Jason, et al.
Publicado: (2020) -
Immunotherapy biomarkers 2016: overcoming the barriers
por: Gulley, James L., et al.
Publicado: (2017)